Bionano Genomics (BNGO) shares plummeted 6.40% in Friday's trading session following the release of its second-quarter earnings report, which revealed mixed results for the advanced medical equipment company. The sharp decline comes as investors digest the company's continued losses and year-over-year revenue decline, despite beating analyst expectations on earnings per share.

The Q2 report showed that Bionano Genomics narrowed its quarterly adjusted loss to $1.99 per share, surpassing analyst projections of a $2.41 loss. However, the company still recorded a substantial quarterly loss of $6.86 million. More concerning for investors was the 13.4% drop in revenue to $6.73 million, slightly missing the expected $6.83 million. This decline in revenue highlights ongoing challenges in the company's market performance and ability to generate sustainable growth.

The negative market reaction to Bionano Genomics' earnings report reflects broader concerns about the company's financial health and future prospects. With the stock already down 81.3% year-to-date prior to this report, investors appear increasingly wary of the company's path to profitability in the competitive advanced medical equipment and technology sector. The continued losses and declining revenue have raised questions about Bionano Genomics' long-term viability and its ability to gain market share in a challenging economic environment.